Processa Pharmaceuticals (NASDAQ:PCSA) Rating Reiterated by HC Wainwright

Processa Pharmaceuticals (NASDAQ:PCSAGet Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 266.97% from the stock’s current price. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($0.45) EPS and Q4 2025 earnings at ($0.45) EPS.

Separately, Benchmark reaffirmed a “speculative buy” rating on shares of Processa Pharmaceuticals in a report on Wednesday, March 6th.

Check Out Our Latest Research Report on PCSA

Processa Pharmaceuticals Price Performance

PCSA opened at $2.18 on Monday. The firm has a market capitalization of $6.23 million, a PE ratio of -0.44 and a beta of 0.53. Processa Pharmaceuticals has a fifty-two week low of $1.40 and a fifty-two week high of $18.00. The company’s 50-day moving average is $2.17 and its 200 day moving average is $5.09.

Processa Pharmaceuticals (NASDAQ:PCSAGet Free Report) last posted its earnings results on Friday, March 29th. The company reported ($0.24) earnings per share for the quarter. As a group, analysts expect that Processa Pharmaceuticals will post -3.82 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Processa Pharmaceuticals stock. Spinnaker Trust acquired a new position in shares of Processa Pharmaceuticals, Inc. (NASDAQ:PCSAFree Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 76,865 shares of the company’s stock, valued at approximately $26,000. Spinnaker Trust owned about 6.25% of Processa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 91.93% of the stock is owned by institutional investors.

Processa Pharmaceuticals Company Profile

(Get Free Report)

Processa Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.

Further Reading

Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.